Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients

Genetics and Molecular Research

Volumn 15, Issue 2, 2016, Pages

  Liu, Q ^a   Chen, H B ^a   Luo, M ^a   Zheng, H ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Hypertension; Left ventricular hypertrophy; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MOK PROTEIN, HUMAN; TUMOR ANTIGEN;

AGED; ARTICLE; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; ECHOCARDIOGRAPHY; GENETICS; HYPERTENSION; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; ODDS RATIO; RISK FACTORS;

EID: 84978676801     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/gmr.15028414     Document Type: Article

References (30)

1. Boulanger E, Wautier MP, Gane P, Mariette C, et al. (2004). The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol. Dial. Transplant. 19: 2208-2216. http://dx.doi.org/10.1093/ndt/gfh277
2. Bucciarelli LG, Wendt T, Qu W, Lu Y, et al. (2002). RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835. http://dx.doi.org/10.1161/01.CIR.0000039325.03698.36
3. Cai W, Sun JF, Liu Y, Xu JX, et al. (2015). Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea. J. Hum. Hypertens. 29: 713-718. http://dx.doi.org/10.1038/jhh.2015.46
4. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, et al. (2003). The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J. Exp. Med. 198: 1507-1515. http://dx.doi.org/10.1084/jem.20030800
5. Cuspidi C, Sala C, Negri F, Mancia G, et al.; Italian Society of Hypertension (2012). Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J. Hum. Hypertens. 26: 343-349. http://dx.doi.org/10.1038/jhh.2011.104
6. Devereux RB (1987). Detection of left ventricular hypertrophy by M-mode echocardiography. Anatomic validation, standardization, and comparison to other methods. Hypertension 9: II 19-26.
7. Germanová A, Koucký M, Hájek Z, Parízek A, et al. (2010). Soluble receptor for advanced glycation end products in physiological and pathological pregnancy. Clin. Biochem. 43: 442-446. http://dx.doi.org/10.1016/j.clinbiochem.2009.11.002
8. Geroldi D, Falcone C, Emanuele E, D’Angelo A, et al. (2005). Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 23: 1725-1729. http://dx.doi.org/10.1097/01.hjh.0000177535.45785.64
9. Goova MT, Li J, Kislinger T, Qu W, et al. (2001). Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159: 513-525. http://dx.doi.org/10.1016/S0002-9440(10)61723-3
10. Gradman AH and Alfayoumi F (2006). From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog. Cardiovasc. Dis. 48: 326-341. http://dx.doi.org/10.1016/j.pcad.2006.02.001
11. Leonardis D, Basta G, Mallamaci F, Cutrupi S, et al. (2012). Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr. Metab. Cardiovasc. Dis. 22: 748-755. http://dx.doi.org/10.1016/j.numecd.2010.11.008
12. Lovic D, Erdine S and Catakoğlu AB (2014). How to estimate left ventricular hypertrophy in hypertensive patients. Anadolu Kardiyol. Derg. 14: 389-395. http://dx.doi.org/10.5152/akd.2014.5115
13. Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, et al. (2009). Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford) 48: 1190-1196. http://dx.doi.org/10.1093/rheumatology/kep199
14. Mancia G, Bombelli M, Facchetti R, Madotto F, et al. (2008). Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. J. Hypertens. 26: 1602-1611. http://dx.doi.org/10.1097/HJH.0b013e328302f10d
15. Mancia G, Fagard R, Narkiewicz K, Redon J, et al. (2013). 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34: 2159-2219. http://dx.doi.org/10.1093/eurheartj/eht151
16. Miyata T, Kurokawa K and Van Ypersele De Strihou C (2000). Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J. Am. Soc. Nephrol. 11: 1744-1752.
17. Nakamura K, Yamagishi S, Nakamura Y, Takenaka K, et al. (2005). Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 70: 137-141. http://dx.doi.org/10.1016/j.mvr.2005.10.002
18. Ozawa M, Tamura K, Okano Y, Matsushita K, et al. (2009). Blood pressure variability as well as blood pressure level is important for left ventricular hypertrophy and brachial-ankle pulse wave velocity in hypertensives. Clin. Exp. Hypertens. 31: 669-679. http://dx.doi.org/10.3109/10641960903407033
19. Pang H, Han B, Li ZY and Fu Q (2015). Identification of molecular markers in patients with hypertensive heart disease accompanied with coronary artery disease. Genet. Mol. Res. 14: 93-100. http://dx.doi.org/10.4238/2015.January.15.12
20. Rosei EA and Muiesan ML (2011). Hypertension and left ventricular hypertrophy. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management 12: 17-18.
21. Schirmer H, Lunde P and Rasmussen K (1999). Prevalence of left ventricular hypertrophy in a general population; The Tromsø Study. Eur. Heart J. 20: 429-438. http://dx.doi.org/10.1053/euhj.1998.1314
22. Schleicher ED, Wagner E and Nerlich AG (1997). Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99: 457-468. http://dx.doi.org/10.1172/JCI119180
23. Taguchi A, Blood DC, del Toro G, Canet A, et al. (2000). Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405: 354-360. http://dx.doi.org/10.1038/35012626
24. Tovillas-Morán FJ, Vilaplana-Cosculluela M, Zabaleta-del-Olmo E, Dalfó-Baqué A, et al. (2010). [Cardiovascular morbidity and mortality and electrocardiographic criteria of left ventricular hypertrophy in hypertensive patients treated in primary care]. Med. Clin. (Barc.) 135: 397-401.
25. Wautier JL and Schmidt AM (2004). Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95: 233-238. http://dx.doi.org/10.1161/01.RES.0000137876.28454.64
26. Wautier MP, Chappey O, Corda S, Stern DM, et al. (2001). Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280: E685-E694.
27. Wautier MP, Boulanger E, Guillausseau PJ, Massin P, et al. (2004). AGEs, macrophage colony stimulating factor and vascular adhesion molecule blood levels are increased in patients with diabetic microangiopathy. Thromb. Haemost. 91: 879-885.
28. Yoon SJ, Park S, Park C, Chang W, et al. (2012). Association of soluble receptor for advanced glycation end-product with increasing central aortic stiffness in hypertensive patients. Coron. Artery Dis. 23: 85-90. http://dx.doi.org/10.1097/MCA.0b013e32834f114e
29. Zhan S, Liu M, Yao W, Hu Y, et al. (2002). [Prevalence and relevant factors on echocardiographic left ventricular hypertrophy among community-based hypertensive patients in Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi 23: 182-185.
30. Zoccali C, Mallamaci F, Asahia K, Benedetto FA, et al. (2001). Pentosidine, carotid atherosclerosis and alterations in left ventricular geometry in hemodialysis patients. J. Nephrol. 14: 293-298.